Improving Outcomes in Chronic Myeloid Leukemia With Early Switch to Second-Generation Generic Tyrosine Kinase Inhibitors: A Study From Resource-Limited Settings in Western India (SOHO 2026) - Sep 1, 2026 - Abstract #CML-1600; "At the last follow-up, 62 patients (52.1%) were receiving imatinib, 47 (39.5%) dasatinib, 5 (4.2%) nilotinib, 3 (2.5%) ponatinib, and 2 (1.7%) bosutinib. Our study shows high rates of switching to dasatinib (39.5%) as a second-line therapy, highlighting the potential future benefit of using it as a first-line therapy for all eligible newly diagnosed patients. Avoiding repeated TKI switches is critical, as it is linked to diminished long-term survival. Current findings suggest that the optimal use of second-generation generic TKIs will lead to significant improvements in long-term survival."
Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology
|
|
Reema Singh 1; Sujay Rainchwar 2; Gautam Makadia 2; Alpesh Kikani 2; Sarang Waghmare 2; Shivam Rainchwar 2; Vijaya Moorthy 2; Divakar Patel 2; Bansi Piparava 2; Mohd Mazhar 1
|